# Rhythm Pharmaceuticals reports sustained BMI reductions in two-year obesity trial

- Link: https://www.directorstalkinterviews.com/rhythm-pharmaceuticals-reports-sustained-bmi-reductions-in-two-year-obesity-trial/4121270063
- Published: 2026-11-20T15:12:00+00:00
- Author: Amilia Stone

Rhythm Pharmaceuticals has reported sustained reductions in body mass index (BMI)
after two years of treatment with setmelanotide in patients with acquired hypothalamic
obesity, with results from its Phase 3 TRANSCEND trial presented at ObesityWeek 
2026.

Patients who received setmelanotide continuously recorded an average BMI reduction
of 18.8% after two years. Those who initially received placebo before switching 
to setmelanotide after 12 months achieved an average reduction of 16.5%.

The results were based on 81 patients who had completed two years of treatment in
the trial’s long-term extension. A total of 125 patients entered the extension, 
with all participants receiving open-label setmelanotide after the first year.

Among adult patients, average BMI reductions reached 21.2% for those treated continuously
and 21.0% for those who switched from placebo. Paediatric patients also recorded
improvements, with BMI z-scores falling by an average of 1.71 and 1.49 respectively
across the two treatment groups.

The safety profile was generally consistent with previous clinical trials of setmelanotide
in acquired hypothalamic obesity.

Acquired hypothalamic obesity is a rare condition caused by damage or dysfunction
affecting the hypothalamus, a region of the brain involved in regulating hunger 
and body weight. It can develop following brain tumours, surgery, traumatic brain
injury or other forms of injury. Patients can experience excessive weight gain, 
persistent hunger and reduced energy expenditure.

Setmelanotide, marketed as IMCIVREE, works by activating the melanocortin-4 receptor
pathway, which plays a role in regulating appetite and energy balance.

Rhythm Pharmaceuticals is held in the portfolio of The Biotech Growth Trust. The
company’s shares represented approximately 2.39% of the trust’s portfolio as at 
31 July 2026, according to the latest holdings information available. The investment
gives the trust exposure to the development and commercialisation of treatments 
for rare obesity and other neuroendocrine conditions.

_**Biotech Growth Trust plc** (LON:BIOG) seeks capital appreciation through investment
in the worldwide biotechnology industry. The Company and the Company’s Portfolio
Manager believe that there is a high congruence between companies that seek to act
responsibly and those that succeed in building long-term shareholder value. _

Share on:
